Principle Diagnostics Celebrates 10 Years of Excellence in Pharmacogenomic Testing

Principle Diagnostics Laboratory, based in Bethlehem, PA, marks a significant milestone as it celebrates a decade of leading advancements in pharmacogenomic (PGx) testing. Over the past ten years, the company has remained dedicated to enhancing medication prescribing through genetic insights, aiming to optimize drug efficacy and reduce adverse reactions.

Since its founding, Principle Diagnostics has focused on the precision and effectiveness of medication management. By analyzing genetic variations, PGx testing at Principle Diagnostics helps predict individual responses to medications. This approach ensures that patients receive personalized treatment tailored to their genetic profiles.

The company has achieved several milestones, starting with the early adoption and integration of PGx testing in 2014. Principle Diagnostics now offers testing for over 100 medications, including those for diabetes, cardiovascular issues, and mental health conditions. The lab prioritizes accessibility, providing non-invasive cheek swabs for sample collection and delivering results within two weeks.

Supporting healthcare providers is a cornerstone of Principle Diagnostics' service. The company offers easy-to-read reports and pharmacist support to help providers utilize PGx results effectively. This not only benefits patients but also contributes to reducing healthcare costs by minimizing emergency visits and hospitalizations.

Looking forward, Principle Diagnostics aims to continue leading innovation in PGx testing. The Right Drug Dose Now Act of 2024 underscores the growing importance of PGx, and the laboratory is well-positioned to make pharmacogenomics a routine aspect of clinical practice.